Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 17, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 550,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,439.5 pence per share; lowest price paid was 1,425 pence per share.
- Treasury Holdings (Settled): 507,110,427 shares (9.31% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,690,427 shares (10.30% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,938,063,984 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 550,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.30% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (507,110,427 settled) against the company's latest annual report.
- Confirm the total voting rights denominator (4,938,063,984 shares) for disclosure threshold calculations.
- Check subsequent filings to confirm the settlement of the 550,000 shares purchased on October 17, 2012.
- Note that this filing does not contain operational or financial performance data for the period.